GNMSF (Genmab AS) 3-Year Book Growth Rate : 19.60% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab AS 3-Year Book Growth Rate?

Genmab AS's Book Value per Share for the quarter that ended in Dec. 2024 was $81.09.

During the past 12 months, Genmab AS's average Book Value per Share Growth Rate was 19.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was 19.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was 20.90% per year. During the past 10 years, the average Book Value per Share Growth Rate was 32.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Genmab AS was 97.40% per year. The lowest was -39.50% per year. And the median was 18.95% per year.

Competitive Comparison of Genmab AS's 3-Year Book Growth Rate

For the Biotechnology subindustry, Genmab AS's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Genmab AS's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Genmab AS 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Genmab AS (OTCPK:GNMSF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Genmab AS 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Genmab AS's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.